Greater Glasgow and Clyde Medicines
Key to symbols The medicine should be initiated by, or on the advice of a specialist, but is suitable for continuation by a GP The medicine should only be used and prescribed by a specialist Indicates the preferred choice within a class or group of medicines
The medicine should be initiated by, or on the advice of a specialist, but is suitable for continuation by a GP
The medicine should only be used and prescribed by a specialist
Indicates the preferred choice within a class or group of medicines
2. Cardiovascular system

2.12. Lipid-regulating drugs

See the NHSGGC Guidelines for the Management of Cholesterol, available on the Clinical Guidelines Directory on StaffNet.

Preferred List
ATORVASTATIN (tablets)

Prescribing Notes:

For guidance on the management of cholesterol for primary and secondary prevention of coronary heart disease and stroke, see the NHSGGC Cholesterol Guidelines.

Excludes chewable tablets.

BNF Link

SIMVASTATIN (tablets)

Prescribing Notes:

  • The MHRA has issued updated advice on prescribing simvastatin based on information relating to the risk of myopathy and rhabdomyolysis. The changes include some additional medicines with which simvastatin is contraindicated and advice on a maximum recommended dose when simvastatin is taken with other medicines.
  • PostScript 71 offers further advice on how to manage patients prescribed simvastatin and these other interacting medicines
  • Caution in renal impairment (see BNF for details).

BNF Link

Total Formulary
EZETIMIBE (tablets)

Restrictions:

Restricted to use in combination with a statin for secondary prevention of coronary heart disease and stroke where the goals of treatment are not met on the maximal tolerated dose of statin, in accordance with the NHSGGC Cholesterol Guidelines (March 2017) (Access to NHSGGC network required to open link).

Prescribing Notes:

Use of ezetimibe as monotherapy and for primary prevention remains non-Formulary.

BNF Link

Specialist and GP
EVOLOCUMAB (injection)

Restrictions:

Restricted to use only on the advice of a lipid specialist in accordance with local protocol (click here) and implementation plan only:

  • in patients with heterozygous familial hypercholesterolaemia (HeFH) and LDL-C ≥5.0 mmol/L for primary prevention of cardiovascular events 
  • in patients with HeFH and LDL-C ≥3.5 mmol/L for secondary prevention of cardiovascular events

Evolocumab is only Formulary when administered at a dose of 140mg every two weeks (i.e. excludes 420mg once monthly dosing).

Prescribing Notes:

Use in other patient groups is subject to ongoing discussion.   All requests for this medicine are to come from lipid clinics.

A summary of key prescribing information for GPs can be found here

BNF Link

Pravastatin

Restrictions:

Restricted to use only in patients in whom drug interactions might pose a problem or for patients who are intolerant of simvastatin and atorvastatin. See the NHSGGC Cholesterol Guidelines.

BNF Link

Specialist and GP
ALIROCUMAB (injection)

Restrictions:

Restricted to use only on the advice of a lipid specialist in accordance with local protocol (click here) and implementation plan only in patients with:

  • heterozygous familial hypercholesterolaemia (HeFH) and LDL-C ≥5.0mmol/L as primary prevention of cardiovascular events
  • or patients with HeFH and LDL-C ≥3.5mmol/L as secondary prevention of cardiovascular event.

Prescribing Notes:

  • Use in other patient groups is subject to ongoing discussion.  All requests for this medicine are to come from lipid clinics.
  • A summary of key prescribing information for GPs can be found here.
  • Wider licensed use of the medicine may not be accepted for use by SMC. See SMC advice for details.

BNF Link

FENOFIBRATE
BEZAFIBRATE
COLESTYRAMINE
ROSUVASTATIN

Restrictions:

Restricted to use only in patients who fail to reach target lipid levels in accordance with the NHSGGC Cholesterol Guidelines or are intolerant of other statins. Doses of 40mg or higher should only be initiated by, or on the advice of a specialist. The use for primary prevention is not recommended by SMC and is non-Formulary.

BNF Link